When: October Q1 FY27 earnings print

Then: Mandatory reassessment regardless of price action; three key data points: (1) organic growth—>2% constructive, <1% confirms structural slowdown; (2) gross margin—recovery above 50.5% signals bottom-in, persistence at ~50% confirms bear thesis; (3) Thorne integration commentary—revenue contribution and margin trajectory

HOLD; Do not add at 146; Wait for 137-140 buy zone (3.3-3.5% yield) or constructive Q1 FY27 print; Maintain 10-25% trim at 150-152

• PG trades at midpoint of 137-167 range, not at a compelling discount—22x earnings and 4.17 PEG ratio signal elevated expectations not supported by 1-3% organic growth guidance
• 10-11% total return thesis (3% yield + 5% dividend growth + 2% buyback) is historical market return, not margin of safety—achievable via 3-month Treasury ladder
• 20% off 2024 highs (167 to 146) represents efficient market repricing of deteriorating fundamentals, not mispricing
• Thorne acquisition at $3.8B for sub-$500M revenue business (7.6x sales) is value-destructive; PG stock is cheaper than the asset being acquired at current levels
• $1B cost headwind from Hormuz situation is unresolved—PG buys petrochemicals, palm oil, paper pulp, and freight all repricing higher; gross margins flat at 50-51% for three years
• Technical setup shows MACD below signal, 10 EMA below 50 SMA, RSI at 49 with declining momentum; bounce volume of 4.36M shares vs 9.5M 30-day average indicates lack of conviction buying
• Adding at 146 risks converting a 5% drawdown into a 15% drawdown before support is established at 137-140

→ vs aggressive: PEG ratio of 4.17 at 22x earnings with 1-3% growth guidance is not 'analytically wrong'—it signals stretched expectations that the compounder thesis ignores

→ vs aggressive: 10-11% total return math is just historical market return dressed as a thesis, not a margin of safety—achievable via risk-free instruments

→ vs aggressive: 20% off highs is evidence of efficient repricing, not mispricing; 70-year dividend record doesn't insulate from multiple compression during regime change

→ vs aggressive: Thorne acquisition at PE exit multiples for a sub-$500M revenue wellness brand is value-destructive capital allocation, not a sensible deal

→ vs aggressive: Hormuz situation is a cost headwind for PG's petrochemical/palm oil inputs, not a pricing power tailwind for the near term

→ vs aggressive: Technical weakness is more serious than acknowledged—volume on bounce is 46% of average, not a sign of mostly-played-out downside

→ vs aggressive: Adding at 146 before support establishes at 137-140 uses up dry powder before the real opportunity arrives

HOLD with tiered scaling framework—small starter add at 146, larger add at 142-140, trim at 150-152, structural exit only below 142 on volume

• Valuation at 22x trailing P/E and 19.8x forward P/E creates legitimate multiple pressure alongside real compounding value from 3% yield, 5% dividend growth, 2% buyback yield, 30% ROE, and 50% gross margins
• FY27 organic growth guide of 1-3% is the lowest in years, creating unresolved multiple overhang until growth re-accelerates or multiple compresses
• Thorne acquisition at $3.8 billion for premium wellness brand is a strategic bolt-on with 18-24 months before integration data clarifies the thesis—moderate optionality, not clear catalyst
• MACD crossed bearish, 10 EMA below 50 SMA, and flat-to-descending 50 SMA are real technical concerns warranting disciplined position management
• 200 SMA at 145.88 with neutral RSI and barely-negative histogram represents a basing pattern, not a confirmed breakdown
• Hormuz situation creates real but two-sided risk: short-term cost pressure on petrochemicals/palm oil/paper pulp/freight versus medium-term defensive bid—neither dominant, both must be underwritten
• Sentiment at 6.3/10 with low confidence lacks retail corroboration; news layer supportive but not conclusive without StockTwits/Reddit confirmation
• 10-25% trim zone at 150-152 is well-calibrated; next 5% upside is more uncertain than prior 5% downside protection
• Clean break below 142 on volume is the structural thesis shift that both aggressive and conservative analysts agree on
• Tiered scaling approach captures asymmetric upside while maintaining risk management—weighted average entry closer to 143 through staged adds rather than all-in or all-out binary

→ vs aggressive: Applying PEG/P/E lens to a compounder is not analytically wrong—it is incomplete but not wrong; the 4.17 PEG tells us the market is paying for durability not yet realized

→ vs aggressive: Desire to add at 146 'in front of the breakdown' is fighting the tape; compressing MACD histograms can precede the next leg down just as easily as a bounce

→ vs aggressive: 5-10% trim at 150-152 is too small if PG rallies on Thorne narrative; meaningful gains would evaporate if multiple compression intensifies

→ vs conservative: Dismissal of compounding mechanics as 'historical average market return dressed up as a thesis' is too dismissive; 3% yield with 5% dividend growth and 2% buyback on 30% ROE is a defensible expected return framing

→ vs conservative: Treating the 20% drawdown as evidence of efficient repricing is more honest about uncertainty than aggressive analyst's mispricing call, but 137-140 target assumes the market gives us that pullback with non-trivial probability it doesn't

→ vs conservative: 70-year dividend track record doesn't insulate from multiple compression during regime change; the franchise is high quality but current price is fair value, not a gift

→ vs conservative: Binary 'no-add-until-137' rule is too rigid; 200 SMA touches with neutral momentum are not distribution tops and warrant flexibility through tiered scaling

→ vs conservative: Thorne call as 'value-destructive at current PG prices' is too strong; private equity exit multiple concerns are real but strategic premium wellness logic is coherent